BioMarin Pharmaceutical Earnings Call Transcripts
Fiscal Year 2026
-
The meeting established a quorum and proceeded with four proposals, including director elections, auditor ratification, executive compensation, and an equity plan amendment. All proposals passed by majority vote, with final results to be published in a Form 8-K.
-
Amicus acquisition completed, boosting 2026 revenue growth outlook to 20% and expanding the commercial portfolio with Galafold and Pombiliti/Opfolda. Q1 revenues rose to $766M, driven by enzyme therapies and Voxzogo, with strong patient demand and new launches supporting future growth.
-
Revenue grew 13% in 2025, with strong performance from Voxzogo and enzyme therapies. Key 2026 catalysts include major phase III readouts, the Amicus acquisition, and new product launches. Commercial focus remains on expanding access, managing competition, and leveraging operational synergies.
-
Revenue grew 13% in 2025, with high single-digit growth expected in 2026. Key pipeline milestones include phase III data for VOXZOGO in hypochondroplasia and BMN 401 for ENPP1 deficiency. The Amicus acquisition is set to expand the portfolio and drive accretion by 2027.
-
A strategic refresh has driven recent acquisitions and a focus on pipeline expansion, with 2026 guidance reflecting competitive and revenue headwinds but projecting solid growth in enzyme therapies and skeletal conditions. Key products like Voxzogo and Palynziq are positioned for continued growth, while new clinical milestones and the Amicus acquisition are expected to drive long-term value.
-
A major transformation has driven strong revenue growth, cost optimization, and a robust pipeline, highlighted by the Amicus acquisition and expansion of Voxzogo. Multiple R&D catalysts and strategic IP defenses position the company for sustained double-digit growth into the 2030s.
Fiscal Year 2025
-
2025 saw 13% revenue growth to $3.22B, led by enzyme therapies and Voxzogo, with strong global expansion and profitability. 2026 guidance projects continued high single-digit growth, new product launches, and integration of Amicus assets, with a focus on innovation and operational efficiency.
-
The acquisition adds two high-growth rare disease therapies, immediately boosting revenue and diversifying the portfolio. The $4.8B all-cash deal, financed partly by debt, is expected to be accretive from 2027, with synergies from global scale and IP protection for Galafold until 2037.
-
Management highlighted strategic transformation, robust pipeline progress, and disciplined cost control, with multiple near-term readouts and global expansion driving growth. Business development targets rare genetic conditions, leveraging a strong global footprint and operational advantages.
-
Raised 2025 revenue guidance and reaffirmed VOXZOGO outlook amid 11% YTD growth and strong cash flow. Divestment of ROCTAVIAN and a $221M IPR&D charge mark portfolio shifts, while 2027 revenue scenarios reflect competitive uncertainties.
-
Recent strategic changes have driven strong revenue growth, pipeline progress, and a successful acquisition. AI is being integrated across operations, and global expansion of key products continues. Regulatory and competitive positioning remain favorable, with a focus on long-term innovation and growth.
-
The session highlighted a strategic R&D transformation, prioritizing high-impact, genetically defined programs and expanding external innovation. Key pipeline updates include BMN333's upcoming pivotal study, rapid progress in hypochondroplasia and ENPP1 deficiency programs, and ambitious efficacy targets for Duchenne muscular dystrophy therapy.
-
Key R&D priorities include advancing BMN 333 for achondroplasia, with pivotal data and a head-to-head study against Voxzogo planned for next year. BMN 401 for ENPP1 deficiency is progressing, with major data readouts and regulatory filings expected in 2024.
-
Q2 2025 saw double-digit revenue and profit growth, driven by strong global demand and new patient starts. Full-year guidance for revenue, margin, and EPS was raised, with VOXZOGO and enzyme therapies leading performance. Pipeline progress and the Inozyme acquisition further support long-term growth.
-
The acquisition of Inozyme Pharma for $270 million brings INZ-701, a late-stage enzyme therapy for ENPP1 deficiency, into the pipeline. The deal is expected to be accretive long-term, with peak revenues of $450–$600 million by the mid-2030s and significant synergies in rare disease markets.
-
Q1 2025 saw 15% revenue growth and 59% higher non-GAAP EPS, driven by VOXZOGO and enzyme therapies. Full-year guidance was reaffirmed, with strong cash flow supporting R&D and commercial expansion. The business remains resilient to external risks and is advancing multiple late-stage programs.
-
Management outlined a clear strategy focused on innovation, growth, and value, targeting $4B revenue by 2027 and 40%+ operating margin by 2026. Voxzogo and enzyme therapies drive growth, with new indications and business development set to expand the portfolio.
-
Management outlined a revamped growth strategy centered on innovation, global expansion, and value creation, with strong financial performance and ambitious long-term targets. Key pipeline advances include new indications for Voxogo, progress in enzyme therapies, and promising early data for BMN 333 and BMN 351.
Fiscal Year 2024
-
Record 2024 growth with 18% revenue increase and 69% EPS rise, driven by Voxzogo and enzyme therapies. 2025 guidance targets 10% revenue growth, $900–$950M from Voxzogo, and margin expansion, with continued pipeline progress and global expansion planned.
-
A comprehensive strategic overhaul has positioned the company for robust growth, with new leadership, a business unit model, and ambitious financial targets. VOXZOGO is set for strong expansion despite competition, while enzyme therapies and ROCTAVIAN benefit from focused strategies and market differentiation.
-
A refreshed strategy emphasizes innovation, growth, and value, with strong leadership and a focus on genetically defined diseases. Enzyme therapies and VOXZOGO drive growth, supported by global expansion and new indications. Pipeline advances include a long-acting CNP and a promising DMD corrector.
-
A comprehensive strategic review led to new business units, a sharpened R&D focus, and ambitious long-term financial targets. ERT and Voxogo franchises are positioned for robust growth, with pipeline and business development efforts set to further enhance value.
-
Record Q3 revenue growth of 28% year-over-year was driven by VOXOGO and enzyme therapies, with profitability and cash flow expanding significantly. Full-year guidance was raised across all metrics, and long-term targets were reaffirmed, supported by strong commercial execution and a robust R&D pipeline.
-
Management presented a revamped strategy focused on innovation, growth, and value, with ambitious financial targets including $4 billion revenue and 40% operating margin by 2027. Growth will be driven by enzyme therapies and Voxzogo, with significant cost transformation and competitive positioning supporting long-term expansion.
-
A new strategy targets $4B revenue by 2027 and mid-teen CAGR through 2034, driven by innovation in skeletal conditions and enzyme therapies, robust pipeline expansion, and a disciplined capital allocation plan. Voxzogo leads growth with multiple new indications, while cost transformation and strong IP underpin competitive positioning.
-
Record Q2 revenue and EPS growth driven by strong Voxzogo and enzyme therapy demand led to raised 2024 guidance. Roctavian strategy now focuses on US, Germany, and Italy, targeting profitability by end of 2025 with reduced expenses. Key pipeline programs advanced and Brineura approval expanded.